Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

The addition of pembrolizumab to docetaxel did not significantly improve efficacy outcomes for participants with previously treated mCRPC. The current standard of care remains unchanged.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-03-05
DOI
https://doi.org/10.1200/jco-24-01283
Citations
34
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
51.62
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Margitta Retz, Ray McDermott, Karim Fizazi, Éric Lévesque et al.
34 citations
Journal of Clinical Oncology
Prostate Cancer Treatment and Research
51.62
article

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Margitta Retz, Ray McDermott, Karim Fizazi, Éric Lévesque, Loı̈c Mourey, Nobuaki Matsubara, Christian Poehlein, Seok‐Soo Byun, Andries M. Bergman, Rustem Gafanov, Andrew J. Armstrong, Howard Gurney, Meital Levartovsky, Daniel Peter Petrylak, Gero Kramer, Ray Manneh Kopp, Charles Schloss, Sergio Bracarda, Paweł Zalewski, Tilman Todenhöfer, Maria De Santis, Russell K. Pachynski, Raffaele Ratta, Xin Tong Li, Ernesto Korbenfeld, Winald R. Gerritsen
article en
34 citations

Abstract

The addition of pembrolizumab to docetaxel did not significantly improve efficacy outcomes for participants with previously treated mCRPC. The current standard of care remains unchanged.

Journal of Clinical OncologyVol. 43(14)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Radboud University Nijmegen (NL), Duke University (US), Washington University in St. Louis (US), Université Paris-Saclay (FR), Lakeridge Health (CA), Sheba Medical Center (IL), Institut Gustave Roussy (FR), TUM Klinikum (DE), Yale Cancer Center (US), Radboud University Medical Center (NL), Seoul National University Bundang Hospital (KR), The Netherlands Cancer Institute (NL), Popular University of Cesar (CO), Cancer Trials Ireland (IE), Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RU), Oncode Institute (NL), St. Vincent's University Hospital (IE), Hôtel-Dieu de Québec (CA), Azienda Ospedaliera S.Maria (IT), Institut Claudius Regaud (FR), National Cancer Center Hospital East (JP), Hospital Británico de Buenos Aires (AR), Hôpital Foch (FR), Université Laval (CA), Medical University of Vienna (AT), Charité - Universitätsmedizin Berlin (DE), Macquarie University (AU)
Openalex Percentile: Top 0%
Prostate Cancer Treatment and Research
51.62
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.